12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Recothrom regulatory update

ZymoGenetics said in an SEC filing that partner Bayer withdrew an MAA for Recothrom as an aid in surgery to improve hemostasis where standard surgical techniques are...

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >